LinkedIn News

Health Insurance

Media & Entertainment

Customer Success

Biotech & Health

Education Technology

Human Resources

Telecommunications

Music Streaming

Entrepreneurship

Cloud Computing

Web Development

Renewable Energy

Renewable Power

Consumer Technology

Agriculture Tech

Machine Learning

Software Development

Environmental Health

Mergers and Acquisitions

Business Development

Government & Policy

Electric Vehicles

Congress Investigates 23andMe Bankruptcy's Impact on Customer Data

Congress Investigates 23andMe Bankruptcy's Impact on Customer Data

The House Committee on Energy and Commerce is probing how 23andMe's recent bankruptcy could affect customer data privacy. Representatives have raised concerns regarding the company's handling of sensitive genetic information in the event of a sale. They pointed out ongoing issues customers face when trying to delete their data, noting that direct-to-consumer firms like 23andMe lack the protections offered by HIPAA. This investigation comes after 23andMe filed for Chapter 11 bankruptcy, with co-founder Anne Wojcicki resigning to pursue a private bid for the company.

Created at: April 19, 2025 9:00pm

Phantom Neuro Secures $19M to Enhance Prosthetic Control for Amputees

Phantom Neuro Secures $19M to Enhance Prosthetic Control for Amputees

Phantom Neuro has raised $19 million to develop its innovative wristband-like device designed to help amputees control their prosthetic limbs. The startup has received FDA designations as a Breakthrough Device and for its TAP program, facilitating its commercialization. Their technology, leveraging the concept of phantom limbs, boasts a 94% accuracy rate in non-invasive tests. With strategic backing from Ottobock and other investors, Phantom aims to expand applications beyond prosthetics. The company has now raised a total of $28 million and plans to enhance its neural interface technology.

Created at: April 15, 2025 1:00pm

Colossal Biosciences Unveils Genetically Engineered Dire Wolves Amid Controversy

Colossal Biosciences Unveils Genetically Engineered Dire Wolves Amid Controversy

Colossal Biosciences has revealed its latest creation, genetically engineered dire wolves, amidst a $10 billion valuation. These animals, based on ancient DNA, are being questioned by scientists regarding their true status as de-extinct species. Co-founder Ben Lamm defends the project, emphasizing both the scientific advancements and ethical considerations taken during the gene editing process. Critics argue that these hybrids do not represent a genuine revival of the species, sparking debate within the scientific community. Colossal aims to pair de-extinction efforts with conservation projects, particularly focusing on red wolves.

Created at: April 8, 2025 5:30pm

Peter Diamandis Envisions a Healthspan Revolution in the Next Decade

Peter Diamandis Envisions a Healthspan Revolution in the Next Decade

Futurist Peter Diamandis predicts that advancements in technology, particularly in AI and cellular medicine, could lead to 'longevity escape velocity' within the next ten years. This concept suggests that as one ages, scientific developments may add more time to one’s life than they consume. While some critics argue that these advancements may primarily benefit the wealthy, Diamandis emphasizes that basic health improvements like diet and exercise are accessible to everyone. He is currently spearheading a $111 million Healthspan XPRIZE aimed at reversing aging in older populations, with over 600 teams competing to showcase innovative solutions.

Created at: April 7, 2025 7:00am

Isomorphic Labs Secures $600M Funding for AI Drug Discovery

Isomorphic Labs Secures $600M Funding for AI Drug Discovery

Isomorphic Labs, the AI drug discovery venture spun out of Google’s DeepMind, has successfully raised $600 million in a funding round led by Thrive Capital, with participation from GV and Alphabet. This marks the first external funding for the company since its inception in 2021. The capital will enhance Isomorphic’s AI drug design capabilities and expedite the transition of its drug discoveries into clinical trials. Founded by DeepMind co-founder Demis Hassabis, the company previously partnered with Eli Lilly and Novartis, potentially unlocking $3 billion in milestone payments. Hassabis emphasized that the funding will facilitate the hiring of top-tier research scientists.

Created at: March 31, 2025 9:00pm

Apple Enhances Health App with AI Coach for Personalized Wellness

Apple Enhances Health App with AI Coach for Personalized Wellness

Apple is reportedly revamping its Health app to introduce an AI coach that will provide personalized health advice using data from users' medical devices. According to Bloomberg's Mark Gurman, development is progressing, with the new features expected to debut alongside iOS 19.4 in spring or summer of 2026. The AI coach, tentatively named Health+, will also incorporate food tracking and is currently being trained using insights from staff physicians. Apple plans to enlist additional doctors to create health-related video content for enhanced user guidance.

Created at: March 30, 2025 9:00pm

23andMe Files for Bankruptcy Protection Amid CEO Resignation

23andMe Files for Bankruptcy Protection Amid CEO Resignation

23andMe, the genetics testing company, has filed for Chapter 11 bankruptcy protection in the U.S., initiating asset sales. Co-founder and CEO Anne Wojcicki announced her resignation to pursue an independent bid for the company. The board believes a court-supervised sale is essential for addressing financial challenges and operational issues. The company, which went public in 2021, has seen its market value plummet over 99%, exacerbated by a significant data breach affecting millions of customers. Currently, its market capitalization stands at approximately $48 million.

Created at: March 24, 2025 7:00am

YC-Backed ReactWise Leverages AI to Revolutionize Drug Manufacturing

YC-Backed ReactWise Leverages AI to Revolutionize Drug Manufacturing

ReactWise, a startup from Cambridge, U.K., is harnessing artificial intelligence to significantly accelerate the drug manufacturing process. By optimizing chemical processes, the AI-driven platform claims to speed up traditional methods by up to 30 times. Co-founder Alexander Pomberger explained that their software simplifies the development of drug recipes by consolidating five years of academic research into an accessible tool. The company is currently running 12 pilot trials with pharmaceutical firms and has raised $3.4 million in pre-seed funding, aiming to enhance efficiency in bringing new drugs to market.

Created at: March 17, 2025 6:00pm

Bryan Johnson Proposes 'Foodome Sequencing' to Ensure Safer Food Choices

Bryan Johnson Proposes 'Foodome Sequencing' to Ensure Safer Food Choices

At SXSW 2025, Bryan Johnson, founder of the Don’t Die movement, introduced the concept of 'foodome sequencing,' aiming to test 20% of foods that make up 80% of the American diet for toxins. Johnson, known for his extreme longevity methods, believes that ensuring clean food is crucial for health. He plans to create a public database to hold brands accountable for unsafe practices. His provocative ideas about AI’s role in extending life have sparked debate, with critics arguing against his extreme measures. Johnson remains undeterred, promoting his lifestyle formula and supplement line.

Created at: March 14, 2025 9:00am

Neko Health Secures $260M Funding, Aims for U.S. Expansion

Neko Health Secures $260M Funding, Aims for U.S. Expansion

Neko Health, the body-scanning startup co-founded by Spotify's Daniel Ek, has raised $260 million in a Series B funding round, valuing the company at $1.8 billion. The funds will facilitate Neko's entry into the U.S. market, expand its clinic network, and enhance its diagnostic technology. With a growing waitlist exceeding 100,000, the startup has already served 10,000 patients across its clinics in Stockholm and London. CEO Hjalmar Nilsonne emphasizes the rising demand for preventative healthcare solutions, indicating a shift in healthcare paradigms. Lightspeed Venture Partners leads the investment, with other notable firms participating.

Created at: January 23, 2025 6:30am

Lindus Health Secures $55M to Transform Clinical Trials with AI

Lindus Health Secures $55M to Transform Clinical Trials with AI

Lindus Health, a London-based startup, has raised $55 million in Series B funding to innovate the clinical trial process. Founded in 2021 and supported by Peter Thiel, the company aims to address inefficiencies in clinical trials through automation and machine learning. Their platform manages the entire clinical trial lifecycle, enhancing both speed and accuracy. With over 35,000 patients enrolled, Lindus plans to expand its operations from the U.K. to the U.S. and improve integration with third-party tools. This funding will also accelerate their AI applications in real-time data analysis.

Created at: January 22, 2025 12:00pm

OpenAI Collaborates with Longevity Startup to Extend Human Lifespan

OpenAI Collaborates with Longevity Startup to Extend Human Lifespan

OpenAI has partnered with Retro Biosciences, a startup focused on longevity science, to develop a new AI model called GPT-4b micro. This model aims to re-engineer Yamanaka factors, proteins that can transform human skin cells into stem cells, potentially extending human life by 10 years. Backed by Sam Altman, Retro has been collaborating with OpenAI for about a year. Unlike Google's Alphafold, this model is specifically designed for biological research. Both companies plan to release findings on the model's capabilities soon.

Created at: January 17, 2025 7:00pm

NeuroBionics Develops Hair-Thin Fibers for Revolutionary Brain Therapy

NeuroBionics Develops Hair-Thin Fibers for Revolutionary Brain Therapy

MIT spinout NeuroBionics is pioneering a minimally invasive technique to treat neurological conditions like depression and Parkinson’s disease. The startup aims to deliver bioelectric fibers, the width of human hair, through blood vessels in the brain, eliminating the need for traditional deep brain surgery. Funded with $5 million, the technology utilizes carbon nanotubes instead of metals, reducing toxicity and improving MRI compatibility. NeuroBionics plans to test its device in pigs before seeking FDA approval, with market entry projected around 2030. Investor Steve Jurvetson highlights the vast potential of this innovation.

Created at: January 16, 2025 5:30pm

Colossal Biosciences Secures $200M to Revive Woolly Mammoths and Other Extinct Species

Colossal Biosciences Secures $200M to Revive Woolly Mammoths and Other Extinct Species

Colossal Biosciences has successfully raised $200 million in a Series C funding round, achieving a remarkable $10.2 billion valuation. This funding was led by TWG Global, with participation from notable investors like Mark Walter and Thomas Tull. The company aims to resurrect woolly mammoths, Tasmanian tigers, and dodo birds using advanced gene-editing technologies. Co-founder Ben Lamm highlighted the impressive technological advancements made since their last funding round. Colossal also plans to develop artificial wombs and collaborate with governments on conservation efforts, anticipating significant revenue from biodiversity credits.

Created at: January 15, 2025 4:00pm

Bioptimus Secures $41M to Create a 'GPT for Biology'

Bioptimus Secures $41M to Create a 'GPT for Biology'

French AI startup Bioptimus has raised $41 million to develop a foundational AI model aimed at understanding and simulating biological processes. This innovative model seeks to predict disease outcomes and enhance treatment strategies by leveraging sensitive clinical data. Co-founder Jean-Philippe Vert highlights its potential across various industries, akin to ChatGPT's capabilities in text generation. Founded just last year, Bioptimus has already accumulated $76 million in funding, showcasing the growing trend of AI investment in France's biotech sector. The latest round was led by Cathay Innovation, with significant participation from various venture firms.

Created at: January 14, 2025 10:30am

Biosphere Innovates Biomanufacturing with UV-C Light Sterilization

Biosphere Innovates Biomanufacturing with UV-C Light Sterilization

Biosphere has developed a bioreactor that utilizes UV-C light for sterilization, aiming to reduce costs and contamination risks in biomanufacturing. The company’s innovative approach replaces traditional steam sterilization, which is energy-intensive and costly. This new technology, part of a $1.5 million Department of Defense project, utilizes bright LEDs to ensure thorough decontamination. Biosphere has raised $8.8 million in seed funding to further its research and development. The startup plans to scale its bioreactor capabilities significantly in the future, potentially transforming the biomanufacturing landscape.

Created at: January 9, 2025 1:00pm

Grove AI Revolutionizes Clinical Trial Enrollment Using AI

Grove AI Revolutionizes Clinical Trial Enrollment Using AI

Grove AI, co-founded by Stanford engineers Tran Le and Sohit Gatiganti, has developed a generative AI solution to streamline clinical trial enrollment. The startup's voice-based agent, Grace, can pre-screen patients and schedule appointments within minutes, significantly reducing the cumbersome traditional processes. In just eight months, Grove AI has engaged with 250,000 patients, leading to 7,000 scheduled visits. Recently, the company secured $5.2 million in seed funding, with investors optimistic about its potential to transform patient data management and reduce bureaucratic obstacles in healthcare.

Created at: January 8, 2025 4:30pm

Siren Secures $9.5M to Advance Smart Socks for Diabetic Foot Ulcer Detection

Siren Secures $9.5M to Advance Smart Socks for Diabetic Foot Ulcer Detection

Siren, a startup focused on diabetic foot ulcer prevention, has raised $9.5 million in a funding round led by Mölnlycke Health Care. The funding aims to enhance the development of Siren Socks, which monitor foot temperature to detect potential injuries in real-time. With this latest investment, the company has raised a total of $43 million. About 830 million people globally have diabetes, with many at risk for ulcers. Siren's technology claims to reduce the risk of ulcers and amputations significantly, reinforcing its potential impact in the biotech market.

Created at: January 8, 2025 11:30am

YC Startup Pharos Secures $5M Seed to Revolutionize Quality Reporting with AI

YC Startup Pharos Secures $5M Seed to Revolutionize Quality Reporting with AI

Pharos, a startup from Y Combinator's summer 2024 cohort, has raised $5 million in a seed round led by Felicis Ventures to streamline hospital quality reporting using AI. Traditional reporting is labor-intensive, often taking nurses hours to complete. Pharos aims to automate this process by extracting data from electronic health records to meet external registry requirements. Co-founders Felix Brann and Matthew Jones, alongside medical doctor Alex Clarke, believe their approach will save hospitals time and money. The funding will help expand their team and enhance product outreach.

Created at: October 25, 2024 3:30pm

Alimetry Secures $18 Million to Advance Wearable Tech for Gastric Disorder Diagnosis

Alimetry Secures $18 Million to Advance Wearable Tech for Gastric Disorder Diagnosis

New Zealand-based startup Alimetry has raised $18 million in Series A funding to enhance its wearable device designed for diagnosing gastric disorders. The non-invasive device uses a flexible electrode array to monitor gut electrical activity, with data analyzed via AI to support clinical diagnostics. Alimetry has already secured FDA approvals and plans to expand its market presence in the U.S. The funding will facilitate further commercialization and development of the technology, which could also aid in diagnosing pediatric and colon-related issues in the future.

Created at: October 24, 2024 4:30pm

Promise Bio Emerges from Stealth with $8.3M Seed Funding

Promise Bio Emerges from Stealth with $8.3M Seed Funding

Promise Bio has officially exited stealth mode, securing $8.3 million in seed funding led by Awz Ventures, along with contributions from Pfizer and AstraZeneca. The Tel Aviv-based biotech firm aims to revolutionize precision medicine for autoimmune diseases through its innovative cloud-based AI platform that detects Post-Translational Modifications (PTMs) in proteins from a single blood sample. This technology significantly streamlines testing, paving the way for more effective treatments. CEO Ronel Veksler emphasizes the need for a shift from outdated trial-and-error methods in managing autoimmune disorders, which affect around 4% of the global population.

Created at: October 23, 2024 3:30pm

Wearable Neurotech: The Next Frontier in Medtech Investment

Wearable Neurotech: The Next Frontier in Medtech Investment

The wearable neurotechnology market is gaining attention as startups like Neurovalens explore non-invasive brain-stimulation therapeutics. This sector, which has raised significantly less funding than invasive technologies, is seen as a cost-effective alternative for treating various conditions, including anxiety, insomnia, and obesity. With projections estimating the market could grow from $14 billion to $40 billion by 2030, investors are increasingly optimistic. Neurovalens, having secured FDA approvals for two devices, plans further clinical trials and product launches, highlighting the potential for wearable neurotech to revolutionize mental health treatments.

Created at: October 13, 2024 12:00pm

Instadeep: Pioneering AI Innovations in Biotech post BioNTech Acquisition

Instadeep: Pioneering AI Innovations in Biotech post BioNTech Acquisition

Instadeep, Africa's largest AI startup, has made remarkable strides since its acquisition by BioNTech for over $550 million. The company focuses on advanced machine learning to enhance biotech applications, including developing AI-driven solutions for cancer therapeutics. Co-founder Karim Beguir emphasized the startup's commitment to deploying AI across BioNTech’s processes, achieving significant improvements in histology and immunotherapy. While Instadeep operates independently, it continues to innovate in both biotech and industrial optimization projects, including railway scheduling and geospatial intelligence. The company aims to leverage AI for societal challenges, such as food security in Africa.

Created at: October 12, 2024 4:00pm

Aktiia's AI-Powered App Transforms Blood Pressure Monitoring with CE Certification

Aktiia's AI-Powered App Transforms Blood Pressure Monitoring with CE Certification

Swiss startup Aktiia has developed a groundbreaking app that enables users to measure blood pressure and heart rate using just their smartphone camera. The app, which received CE certification, utilizes generative AI trained on 11 billion data points to provide accurate readings in just 90 seconds. This innovative solution eliminates the need for bulky cuffs, making hypertension monitoring more accessible. Aktiia's technology aims to revolutionize blood pressure management, potentially saving lives and healthcare costs. The app is expected to launch in 2025, following successful funding rounds totaling $59.7 million.

Created at: October 11, 2024 3:00pm

MiLaboratories Secures $10M Funding to Revolutionize Genomic Research

MiLaboratories Secures $10M Funding to Revolutionize Genomic Research

San Francisco-based MiLaboratories has raised $10 million in Series A funding to enhance its computational biology platform designed for genomic research. The platform simplifies the analysis of vast genomic data, integrating features like data visualization and generative AI. MiLaboratories aims to empower bioinformaticians, allowing them to focus on complex tasks rather than routine data processing. Currently in use by around 300 labs, the platform also facilitates third-party app development. With major pharma companies as clients, the startup is poised to make significant advancements in vaccine and cancer treatment research.

Created at: October 10, 2024 8:00am

BaCta Pioneers Bio-Engineered Natural Rubber to Slash CO2 Emissions

BaCta Pioneers Bio-Engineered Natural Rubber to Slash CO2 Emissions

Paris-based startup baCta is revolutionizing natural rubber production using engineered E.coli bacteria, aiming for a carbon-neutral process. Recently securing €3.3 million in funding, baCta plans to scale its lab-based methods to meet industrial demands. The initiative addresses sustainability concerns with synthetic rubber while offering a hypoallergenic alternative. CEO Mathieu Nohet believes this innovation can significantly reduce CO2 emissions and provide competitive pricing. Initially targeting luxury fashion brands, baCta aims to expand into broader industrial applications. The startup plans to reach pilot scale within 18 months, paving the way for further growth.

Created at: October 10, 2024 7:00am

Basecamp Research Secures $60M for Ambitious AI Project in Biology

Basecamp Research Secures $60M for Ambitious AI Project in Biology

Basecamp Research, a London-based startup, has raised $60 million in Series B funding to develop an AI platform designed to advance biological research. Founded by biology PhDs, the company aims to build a 'GPT for biology' by collecting primary data from the natural world. CEO Glen Gower emphasized the need to address the significant data gap in biological models. With over 100 partnerships across 25 countries, Basecamp plans to collaborate with the Broad Institute to enhance drug discovery and biodiversity insights. The funding will facilitate data expansion and model development.

Created at: October 9, 2024 11:00am

French Biotech Generare Raises €5M to Revolutionize Drug Discovery

French Biotech Generare Raises €5M to Revolutionize Drug Discovery

French biotech startup Generare has successfully closed a €5 million seed funding round to enhance its innovative platform for drug discovery. The startup focuses on identifying natural molecules produced by microorganisms, utilizing advanced genetic engineering techniques. Generare has already uncovered over 1,000 genetic recipes, including novel compounds with antibiotic properties. Its scalable approach promises to expedite the analysis of genetic material, potentially leading to groundbreaking pharmaceutical developments. The company aims to industrialize its processes while addressing crucial antibiotic resistance challenges in the healthcare sector.

Created at: October 8, 2024 8:14am